Agenus Inc., including its subsidiaries, (Agenus) is a biotechnology company focused on the development and commercialization of technologies to treat cancers and infectious diseases. The Company's core technology portfolio consists of its Saponin Platform (based on its saponin adjuvant based technologies) and its Heat Shock Protein (HSP) Platform (based on its HSP based technologies). The Company's key candidates from these technology platforms include QS-21 Stimulon adjuvant (QS-21), the Prophage Series vaccines and HerpV. The Company's products and technologies under development include QS-21. A number of pharmaceutical and biotechnology companies have licensed QS-21 from the Company for use in vaccines to treat a wide variety of human diseases. The Company has retained worldwide manufacturing rights for QS-21. In February 2014, Agenus Inc. completed the acquisition of 4-Antibody AG.